Exagen Inc
XGN
Company Profile
Business description
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Contact
1261 Liberty Way
VistaCA92081
USAT: +1 760 560-1501
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
179
Stocks News & Analysis
stocks
16 ASX stocks to buy and hold forever, revisited
This time last year, I highlighted 16 ASX stocks that investors could own indefinitely. One year on, I look at whether there should be any changes to the list of stocks as well as which companies are worth buying now.
stocks
This ASX200 reject could be a contrarian buying opportunity
Johns Lyng’s interim results and index deletion have sent investors running for the exits. Our analyst Esther Holloway thinks the sell-off is overdone.
stocks
A 15 step checklist from Buffett's forgotten inspiration
Phil Fisher achieved remarkable stock market returns by holding high quality growth companies for long periods of time. Here's how he found them.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,982.40 | 121.00 | -1.49% |
| CAC 40 | 7,941.91 | 105.69 | -1.31% |
| DAX 40 | 22,328.77 | 292.18 | -1.29% |
| Dow JONES (US) | 41,433.48 | 478.23 | -1.14% |
| FTSE 100 | 8,495.99 | 104.23 | -1.21% |
| HKSE | 23,721.52 | 60.62 | -0.25% |
| NASDAQ | 17,436.10 | 32.22 | -0.18% |
| Nikkei 225 | 36,898.83 | 105.72 | 0.29% |
| NZX 50 Index | 12,273.83 | 137.14 | -1.10% |
| S&P 500 | 5,572.07 | 42.49 | -0.76% |
| S&P/ASX 200 | 7,763.40 | 126.70 | -1.61% |
| SSE Composite Index | 3,374.08 | 5.75 | -0.17% |